rss
J Clin Pathol doi:10.1136/jclinpath-2012-200667
  • PostScript
  • Correspondence

Authors' response: ‘Focusing on HER2 as a potential therapeutic target in primary ovarian mucinous carcinomas’

  1. Gkeok Stzuan Diana Lim
  1. Department of Pathology, National University Health System and National University of Singapore, Singapore
  1. Correspondence to Dr Gkeok Stzuan Diana Lim, Department of Pathology, National University Health System and National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Republic of Singapore; diana_gz_lim{at}nuhs.edu.sg

In a study involving a large series of epithelial ovarian carcinomas (EOCs), McCaughan et al1 reported human epidermal growth factor receptor 2 (HER2) protein overexpression and amplification in all major histological subtypes, an observation consistent with the literature.2 3 Specifically, they document HER2 gene amplification in 3.0% (7/259) of serous papillary carcinomas, 2.1% (2/92) of endometrioid carcinomas, 25.0% (3/12) of mucinous carcinomas, 4.0% (1/25) of clear cell carcinomas and 11.9% (7/60) of mixed type carcinomas. Although their number of mucinous carcinomas was low (n=12), the higher prevalence of HER2 gene amplification relative to the other histological subtypes is also consistent with the literature.4 5

We had previously reported similar findings of primary ovarian mucinous carcinomas having the highest prevalence of HER2 …

Relevant Article


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article